V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Venetoclax and Navitoclax in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Thomas B. Alexander,Norman J. Lacayo,Vinod Pullarkat,Elias Jabbour,Seong Lin Khaw,Charles G. Mullighan,Ashish Bajel,Jessica Leonard,Robin E. Norris,Jeffrey E. Rubnitz,Susan I. Vear,Michelle Schmidt,Bo Tong,Ying Zhou,Jeremy A. Ross,Lindsey Rosenwinkel,Amanda Jacobson,Su Young Kim,Wendy Stock +18 more
TL;DR: The addition of Nav to Ven has shown synergistic effects in preclinical models and might mitigate the dose-limiting thrombocytopenia associated with Nav monotherapy, and this phase 1, multicenter, open-label, dose escalation study enrolled nine patients with relapsed or refractory ALL.
Journal ArticleDOI
Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Drew J. Winston,Jo Anne H. Van Burik,Vinod Pullarkat,Genovefa A. Papanicolaou,Ravi Vij,E.A. Vance,George Alangaden,Roy F. Chemaly,Finn Bo Petersen,Nelson J. Chao,Jared Klein,Kellie Sprague,Carolyn Dougherty,Stephen Villano,Michael Boeckh +14 more
TL;DR: Maribavir prophylaxis reduced the rate of CMV infection compared to placebo, with a favorable safety profile in this complex patient population, and Phase 3 studies of maribavIR in stem cell and solid organ transplant recipients are being planned.
Journal ArticleDOI
Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital
Rohan Gupta,Rohan Gupta,Tamer Othman,An Uche,I. Amanam,I. Amanam,Chen Chen,Larissa Celles,Gregorianna Lane,Matthew Mei,Ibrahim Aldoss,Vinod Pullarkat,Phyllis Kim,James Yeh +13 more
TL;DR: Risk stratification and evidence-based treatment approaches are important for patients with ALL treated in a resource-limited setting and partnership with a cancer center with early referral for HCT can facilitate curative HCT to be performed.
Journal ArticleDOI
Self-administration of romiplostim in patients with chronic immune thrombocytopenia
Deirdra R. Terrell,James N. George,James B. Bussel,Roger M. Lyons,Vinod Pullarkat,Robert L. Redner,Dominik Selleslag,Kun Nie,Paul Woodard +8 more
TL;DR: This study aims to demonstrate the importance of knowing the carrier and removal status of canine coronavirus to the prognosis of other types of cancer.
Journal ArticleDOI
Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?
Ibrahim Aldoss,Vinod Pullarkat +1 more
TL;DR: The role of allogeneic HCT consolidation must be re-examined in the context of some key advances in ALL management, including the introduction of minimal residual disease (MRD) monitoring and classifying ALL using nextgeneration sequencing approaches in addition to cytogenetics.